Darolutamide + ADT for Metastatic Hormone-Sensitive Prostate Cancer: ARASEC
This Medudy course is a video tutorial for physicians on the topic of “Darolutamide + ADT for Metastatic Hormone-Sensitive Prostate Cancer (ARASEC).” The format used here is a “Journal Club Summary,” in which we summarize the latest and most clinically relevant studies for you. In metastatic hormone-sensitive prostate cancer (mHSPC), the combination of an androgen receptor pathway inhibitor (ARPI) […]